Amgen, Genzyme race to develop new manufacturing process

Manufacturing biotech drugs inside living cells is a complex and expensive task. But two big outfits, Amgen ($AMGN) and Sanofi's ($SNY) Genzyme, are racing to develop a new process that promises to significantly reduce the cost of proteins and antibodies, according to a story in MIT's Technology Review. Amgen has been playing its cards close to the vest, but Genzyme has been public about its effort to change from batch production to continuous production, looking for economies that have helped transform other industries. "There's a race going on," says Konstantin Konstantinov, Genzyme's vice president for late-stage product development. "We're trying to come up with the dominant design." Feature

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.